A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
15actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-11 | actual | When the study began enrolling |
| Primary completion | 2026-08-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-03 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Adults
Interventions
- Drug: Tafamidis
- Drug: Tafamidis
- Drug: Tafamidis
Primary outcomes
what the primary-completion date above is the date OFArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of tafamidis
measured Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose
Maximum Observed Plasma Concentration (Cmax)of tafamidis.
measured Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed